Summary
Structural modification of the N10 position of 4-amino folates affects mediated membrane transport in mammalian cells but has little or no effect on target enzyme (dihydrofolate reductase) inhibition. Some of these modifications have been associated with differential effects on transport in various cell types in a manner which favored greater accumulation and persistence of drug in reponsive tumor cells than in normal proliferative tissue. With the aim of identifying new structures with greater potential for differential mediated accumulation, we have studied three new 10-alkyl analogs of 10-deaza-aminopterin. Two of these analogs showed therapeutic efficacy substantially greater than 10-deaza-aminopterin, an analog with antitumor properties superior to methotrexate. These analogs, the 10-methyl, 10-ethyl, and 10,10-dimethyl derivatives, were equivalent to the parent compound, 10-deaza-aminopterin, and aminopterin, and slightly more potent than methotrexate, as inhibitors of L1210 cell dihydrofolate reductase. The three new analogs, 10-deaza-aminopterin, and aminopterin exhibited similar transport properties in L1210, Ehrlich, and S180 cells. Efflux and influx Vmax were similar to those of methotrexate, but influx Km was 4- to 14-fold lower than for methotrexate. That is, substitution at N10, but not at C10, reduced influx potential in these tumor cells. These differences in transport properties among this group of analogs which determine net accumulation were reflected in the individual values for growth-inhibitory potency. In contrast to that seen in tumor cells, alkylation at both N10 and C10 reduced influx potential (increased Km) in isolated intestinal epithelial cells from mouse small intestine. Influx was in the order aminopterin >10-deaza-aminopterin with further reduction in each series showing a magnitude in proportion to the size of the 10 substituent. Otherwise, influx Vmax and efflux were similar for the group. Accumulation of polyglutamates in small intestine was greater following aminopterin administration than following administration of other analogs (10-ethyl, 10-deaza-aminopterin < methotrexate < 10-deaza-aminopterin). Polyglutamate accumulation for all the analogs was greater in tumor cells, but accumulation of each varied between the two tumors (L1210 and S180) examined. Differences among the analogs were not as great in L1210 as in S180 cells, and their metabolism was not in the same relative order. Plasma pharmacokinetics for 10-methyl and 10-ethyl derivatives were similar to those for 10-deaza-aminopterin and methotrexate. The 10,10-dimethyl analog was cleared more rapidly.
As in our prior reports, a greater selective action of some of the new analogs was associated with increased persistence of the analog in tumor versus small intestine. The greatest differential in persistence was found with analogs which had a lower value for influx Km in tumor but a higher value in intestinal epithelium. Two analogs (10-deaza-aminopterin and 10-ethyl, 10-deaza-aminopterin) which exhibited identical transport properties but different extents of polyglutamylation had pharmacokinetics in tumor that were indistinguishable. However, the analog that was more rapidly polyglutamylated (10-ethyl, 10-deaza-aminopterin) was therapeutically more effective.
Similar content being viewed by others
References
Borsa J, Whitmore GF, Valeriote FA, Collins D, Bruce WR (1969) Studies on the persistence of methotrexate, cytosine, arabinoside and leucovorin in serum of mice. J Natl Cancer Inst 42: 235
Cashmore AR, Dreyer RN, Horvath C, Knipe JO, Coward JK, Bertino JR (1980) Separation of pteroyl-oligo-γ-l-glutamates by high-performance liquid chromatography. Methods Enzymol 66: 459
Chello PL, Sirotnak FM, Dorick DM, Donsbach RC (1977) Therapeutic relevance of differences in the structural specificity of the transport systems for folate analogs in L1210 tumor cells and in isolated murine intestinal epithelial cells. Cancer Res 37: 4297
Chello PL, Sirotnak FM, Dorick DM (1980) Alterations in the kinetics of methotrexate transport during growth of L1210 murine leukemia cells in culture. Mol Pharmacol 18: 274
DeGraw JI, Kisliuk RL, Baugh CM, Nair MG (1974) Synthesis and antifolate activity of 10-deaza-aminopterin. J Med Chem 17: 552
DeGraw JI, Brown VH, Tagawa H, Kisliuk RL, Gaumont Y, Sirotnak FM (1982) Synthesis and antitumor activity of 10-alkyl, 10-deaza-aminopterin. A convenient synthesis of 10-deaza-aminopterin. J Med Chem 251: 1227
Goldman ID (1975) Analysis of the cytotoxic determinants for methotrexate [NSC-740]. A role for “free” intracellular drug. Cancer Chemother Rep 6: 51
Goldman ID (1981) Membrane transport considerations in high-dose methotrexate regimens with leucovorin resine. Cancer Treat Rep 65: 13
Henderson PFJ (1973) Steady-state enzyme kinetics with high-affinity substrates or inhibitors. A statistical treatment of dose-response curves. Biochem J 135: 101
Margolis S, Philips FS, Sternberg SS (1971) The cytotoxicity of methotrexate in mouse small intestine in relation to inhibition of folic reductase and of DNA synthesis. Cancer Res 31: 2037
Piper JR, McCaleb GS, Montgomery JA, Kisliuk RL, Gaumont Y, Sirotnak FM (1982) 10-Propargylaminopterin and alkyl homologues of methotrexate as inhibitors of folate metabolism. J Med Chem 25: 877
Poser RG, Sirotnak FM, Chello PL (1981) Differential synthesis of methotrexate polyglutamates in normal proliferative and neoplastic mouse tissues in vivo. Cancer Res 41: 4441
Sirotnak FM (1980) Correlates of folate analog transport, pharmacokinetic and selective antitumor action. Pharmacol Ther 8: 71
Sirotnak FM, Donsbach RC (1973) Differential cell permeability and the basis for selective activity of methotrexate during therapy of the L1210 leukemia. Cancer Res 33: 1290
Sirotnak FM, Donsbach RC (1975) Further evidence for a basis of selective activity and relative responsiveness during antifolate therapy of murine tumors. Cancer Res 35: 1737
Sirotnak FM, Donsbach RC (1976) Kinetic correlates of methotrexate transport and therapeutic responsiveness in murine tumors. Cancer Res 36: 1151
Sirotnak FM, Moccio DM (1980) Pharmacokinetic differences in methotrexate sensitivity of normal proliferative tissues in the mouse. Cancer Res 40: 1230
Sirotnak FM, Chello PL, Brockman RW (1979) Potential for exploitation of transport systems in acnticancer drug design. Methods Cancer Res 16: 382
Sirotnak FM, Chello PL, DeGraw JI, Piper JR, Montgomery JA (1981) Membrane transport and the molecular basis for selective antitumor action of folate analogs. In: Sartorelli A (ed) Molecular actions and targets for cancer chemotherapeutic agents. Academic Press, New York, p 349
Sirotnak FM, Moccio DM, Goutas LJ, Kelleher LE, Montgomery JA (1982a) Biochemical correlates of responsiveness and collateral sensitivity of some methotrexate resistant murine tumors to the lipophilic antifolate, metoprine. Cancer Res 42: 924
Sirotnak FM, DeGraw JI, Moccio DM, Dorick DM (1982b) Antitumor properties of a new folate analog, 10-deaza-aminopterin, in mice. Cancer Treat Rep 62: 1047
Sirotnak FM, DeGraw JI, Chello PL, Moccio DM, Dorick DM (1982c) Biochemical and pharmacologic properties of a new folate analog, 10-deaza-aminopterin, in mice. Cancer Treat Rep 66: 351
Sirotnak FM, DeGraw JI, Schmid FA, Goutas LJ, Moccio DM (1983) New folate analogs of the 10-deaza-aminopterin series. Further evidence for markedly increased antitumor efficacy compared to methotrexate in ascitic and solid murine tumor models. Cancer Chemother Pharmacol 12: 26–30
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sirotnak, F.M., DeGraw, J.I., Moccio, D.M. et al. New folate analogs of the 10-deaza-aminopterin series Basis for structural design and biochemical and pharmacologic properties. Cancer Chemother. Pharmacol. 12, 18–25 (1984). https://doi.org/10.1007/BF00255903
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00255903